{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-090567","form_type":"8-K","ticker":"CTSO","cik":"0001175151","company_name":"Cytosorbents Corp","filed_at":"2024-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.345643+00:00","generated_at":"2026-05-31T08:48:01.764404+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CytoSorbents appoints Peter J. Mariani as CFO; Kathleen P. Bloch retires","bullets":["Peter J. Mariani appointed CFO effective Aug 14, 2024; previously CFO of Axogen (2016-2023).","Mariani receives base salary of $425,000, cash bonus up to 45%, and inducement awards of stock options & RSUs.","Kathleen P. Bloch retired as CFO and will serve as consultant at $335/hour through Dec 31, 2025.","CEO highlights Mariani's experience as company pursues U.S. FDA/Health Canada approval for DrugSorb-ATR."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-090567","json":"https://secwatch.observer/filing/0001104659-24-090567.json","markdown":"https://secwatch.observer/filing/0001104659-24-090567.md","text":"https://secwatch.observer/filing/0001104659-24-090567.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924090567/0001104659-24-090567-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924090567/tm2421901d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:48:01.764404+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"30b1c0d47b","claim":"Kathleen P. Bloch retired as Chief Financial Officer at Cytosorbents Corp.","evidence_excerpt":"the Company also announced the retirement of Ms. Kathleen P. Bloch, the Company’s then serving Chief Financial Officer, and her transition into a consulting role with the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924090567/0001104659-24-090567-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"a6327df306","claim":"Peter J. Mariani was appointed as Chief Financial Officer at Cytosorbents Corp.","evidence_excerpt":"On August 13, 2024, CytoSorbents Corporation (the “Company”) issued a press release announcing the appointment of Peter J. Mariani as the Company’s new Chief Financial Officer, effective as of August 14, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924090567/0001104659-24-090567-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}